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C L I N I C A L  I N Q U I R I E S
What medications are effective for treating
symptoms of premenstrual syndrome (PMS)?
EVIDENCE-BASED ANSWER Vitamin B6 (50–100
mg/d) and elemental calcium (1200 mg/d) are safe,
inexpensive, and moderately effective (Table) (grade
of recommendation: B). Selective serotonin reuptake
inhibitors (SSRIs) and some other antidepressants
are more effective, but are also more costly and
more likely to cause side effects or treatment
dropout (grade of recommendation: A).
Antidepressant dosing only during the luteal phase
may be effective and more tolerable (grade of rec-
ommendation: B). Alprazolam (generally 0.25–0.5
mg 3 times a day during luteal phase) may be effec-
tive for treating mood or anxiety symptoms (grade
of recommendation: B). Hormonal therapies (oral
contraceptives, gonadotropin-releasing hormone
agonists, danazol, estrogen) lack convincing evi-
dence of efficacy and cause many side effects; prog-
esterone is no more beneficial than placebo (grade
of recommendation: B). There is no convincing evi-
dence of benefit from diuretics, magnesium, beta-
blockers, or lithium (grade of recommendation: C). 
EVIDENCE SUMMARY Pooled results of 9, gener-
ally poor-quality studies of Vitamin B6 show some
benefit.1 Doses higher than 100 mg/d may cause
peripheral neuropathy. Three small studies in the
1980s suggested possible benefit of Vitamin E; how-
ever, these studies have not been further replicated.
One well-designed, randomized controlled trial of
calcium therapy showed > 50% decrease in symp-
tom complex scores after 3 months in more than half
of subjects taking 1200 mg/d supplemental elemen-
tal calcium (NNT=6).2
Among SSRIs, fluoxetine (20 mg/d) is well-studied
and effective.3 Other SSRIs, including sertraline,
paroxetine, fluvoxamine, and venlafaxine, and
clomipramine (a tricyclic with serotonin reuptake
inhibitor activity), also show benefit but are less well
studied. Luteal phase-only dosing may be equally or
more effective than continuous dosing for some
SSRIs. Benzodiazepines have shown mixed results in
treating PMS, and overall their benefit appears small-
er than that of SSRIs.4 Luteal phase-only dosing the-
oretically reduces the risk of benzodiazepine
withdrawal or dependence, but published data
are rare.
Gonadotropin-releasing hormone agonists
may be effective, but troublesome anti-estrogenic
side effects limit their utility. Estrogen and prog-
esterone “add-back” therapy to counter side
effects further complicates this approach. The
gonadotropin inhibitor danazol has a high treat-
ment dropout rate at higher doses (200–400 mg/d
continuously), but can be effective in individuals
who are able to tolerate it3,5; however, danazol is
expensive and causes significant androgenic side
effects. Lower-dose danazol (200 mg/d luteal
phase only) is better tolerated but ineffective.6 A
meta-analysis of progesterone found no evidence
to support its efficacy.7 Oral contraceptives are
ineffective for global symptoms, and may actual-
ly cause PMS symptoms in some women.
RECOMMENDATIONS FROM OTHERS The
American College of Obstetricians and
Gynecologists recommend that patients with mild to
moderate PMS should receive supportive, lifestyle,
and dietary interventions. For severe PMS, SSRIs are
the initial drug of choice. Alprazolam may be useful
when these interventions are ineffective. Consider
oral contraceptives for primarily physical symptoms
and reserve gonadotropin-releasing hormone for
severe cases unresponsive to other treatments.8
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TA B L E
Agents for treating symptoms 
of premenstrual syndrome
Sample drug 
Medication and dose Adverse effects Benefit 
Vitamin B61 50–100 mg/d Peripheral OR = 2.32 (95% CI 
neuropathy 1.95–2.54)
Elemental 1200 mg/d Same as placebo NNT = 6 for 50% 
calcium2 symptom reduction
SSRIs3 Fluoxetine Insomnia, headache, NNT = 4–11
20 mg/d nausea, dizziness
Benzodiazepines4 Alprazolam Habituation NNT = 3 for 50% 
0.25–0.5 mg  symptom reduction
tid/qid in  
luteal phase
GnRH agonists5 Danazol Hypoestrogenic Benefit unclear
200–400 mg/d Androgenic Benefit unclear
GnRH, gonadotropin-releasing hormone; NNT, number needed to treat; SSRIs, selective serotonin reuptake inhibitors.
